ArticleParasitology research2003
The monocyte locomotion inhibitory factor produced by Entamoeba histolytica inhibits induced nitric oxide production in human leukocytes.
Article in Parasitology research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 41 citations in OpenAlex.
- Functional Characterization of an Interferon Gamma Receptor-Like Protein on Entamoeba histolytica.Infection and immunity · 2019Article
- Article
- Immune Evasion Mechanisms of Entamoeba histolytica: Progression to Disease.Frontiers in microbiology · 2015Review
- Peroxynitrite and peroxiredoxin in the pathogenesis of experimental amebic liver abscess.BioMed research international · 2014Review
- Host immune response to intestinal amebiasis.PLoS pathogens · 2013Review
- Monocyte locomotion inhibitory factor produced by E. histolytica improves motor recovery and develops neuroprotection after traumatic injury to the spinal cord.BioMed research international · 2013Article
- Intestinal microbial community diversity between healthy and orally infected rabbit with Entamoeba histolytica by ERIC-PCR.Parasitology research · 2012Article
- Glucose starvation boosts Entamoeba histolytica virulence.PLoS neglected tropical diseases · 2011Article
- Anti-inflammatory defense mechanisms of Entamoeba histolytica.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2011Review
- Crosstalk at the initial encounter: interplay between host defense and ameba survival strategies.Current opinion in immunology · 2007Review
- Cytokine expression in CD4(+) cells exposed to the monocyte locomotion inhibitory factor produced by Entamoeba histolytica.Parasitology research · 2006Article
- Presence and Interactions ofIranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The monocyte locomotion inhibitory factor, an anti-inflammatory pentapeptide produced by Entamoeba histolytica, inhibits the in vitro production of nitric oxide induced by cytokines (INF-gamma, TNF-alpha) or PMA in human leukocytes. This can be added to the other previously reported functional effects of this factor, such as the inhibition of monocyte locomotion and the synthesis of reactive oxygen intermediates in both monocytes and neutrophils. The decreased nitric oxide production may interfere with the killing of amebas by neutrophils in the early invasive stages of amebiasis, when oxidative mechanisms are used [reactive oxygen and nitrogen intermediates either individually or synergistically via peroxynitrite (ONOO(-))], and in the advanced stages, when both non-oxidative and oxidative (including nitric oxide) mechanisms are employed by macrophages. Diminished nitric oxide production by leukocytes may also contribute to the paucity of late inflammatory components in amebic abscess of the liver and other amebic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.